---
figid: PMC4209854__emss-60583-f0003
figlink: /pmc/articles/PMC4209854/figure/F3/
number: F3
caption: 'Three strategies are used to antagonise aberrant EGFR signalling. First,
  monoclonal antibodies bind the extracellular domain of epidermal growth factor (EGF)
  receptors and prevent endogenous ligand engagement, thereby attenuating downstream
  pathway activation (cetuximab and trastuzumab). Secondly, small molecule tyrosine
  kinase inhibitors target the intracellular portion of EGF receptors; in the absence
  of kinase activity EGFR autophosphorylation and downstream signalling is inhibited
  (erlotinib, gefitinib, lapatinib, HKI-272 and BIBW-2948). Finally, small molecule
  inhibitors which target specific downstream EGFR signalling pathway components have
  also been developed and may exhibit clinical efficacy in chronic respiratory disease
  (ARRY-142886, PX-866, rapamycin, SDZ RAD, everolimus, ruxolitinib, perifosine, selumetinib
  and sorafenib). PI3K: phosphatidylinositol-3-kinase; PIP3: phosphatidylinositol
  (3,4,5)-triphosphate; Akt: protein kinase B; GSK3: glycogen synthase kinase 3; mTOR:
  mammalian target of rapamycin; MEK: MAPK kinase; ERK: extracellular signal-regulated
  kinase; JAK: Janus kinase; STAT: signal transducer and activator of transcription.'
pmcid: PMC4209854
papertitle: 'Targeting EGFR signalling in chronic lung disease: therapeutic challenges
  and opportunities.'
reftext: Sabari Vallath, et al. Eur Respir J. ;44(2):513-522.
pmc_ranked_result_index: '14964'
pathway_score: 0.9604328
filename: emss-60583-f0003.jpg
figtitle: 'Targeting EGFR signalling in chronic lung disease: therapeutic challenges
  and opportunities'
year: ''
organisms:
- Homo sapiens
ndex: c2673bff-deba-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4209854__emss-60583-f0003.html
  '@type': Dataset
  description: 'Three strategies are used to antagonise aberrant EGFR signalling.
    First, monoclonal antibodies bind the extracellular domain of epidermal growth
    factor (EGF) receptors and prevent endogenous ligand engagement, thereby attenuating
    downstream pathway activation (cetuximab and trastuzumab). Secondly, small molecule
    tyrosine kinase inhibitors target the intracellular portion of EGF receptors;
    in the absence of kinase activity EGFR autophosphorylation and downstream signalling
    is inhibited (erlotinib, gefitinib, lapatinib, HKI-272 and BIBW-2948). Finally,
    small molecule inhibitors which target specific downstream EGFR signalling pathway
    components have also been developed and may exhibit clinical efficacy in chronic
    respiratory disease (ARRY-142886, PX-866, rapamycin, SDZ RAD, everolimus, ruxolitinib,
    perifosine, selumetinib and sorafenib). PI3K: phosphatidylinositol-3-kinase; PIP3:
    phosphatidylinositol (3,4,5)-triphosphate; Akt: protein kinase B; GSK3: glycogen
    synthase kinase 3; mTOR: mammalian target of rapamycin; MEK: MAPK kinase; ERK:
    extracellular signal-regulated kinase; JAK: Janus kinase; STAT: signal transducer
    and activator of transcription.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK1
  - AKT3
  - AKT1
  - MTOR
  - PIK3R6
  - PIK3R5
  - GSK3A
  - PIK3R4
  - MAPK3
  - STAT6
  - AKT2
  - RRAD
  - GSK3B
  - JAK1
  - JAK2
  - HRAS
  - KRAS
  - NRAS
  - MAP2K1
  - MAP2K2
  - STAT2
  - PIK3CA
  - PIK3CB
  - STAT5B
  - PIK3CG
  - ARAF
  - RAF1
  - BRAF
  - STAT1
  - JAK3
  - TYK2
  - STAT4
  - STAT5A
  - PIK3CD
  - STAT3
  - PIK3R3
  - Perifosine
  - ARRY-142886
  - Selumetinib
  - Ruxolitinib
  - Rapamycin
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3A
  entrez: '2931'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT6
  entrez: '6778'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAD
  symbol: RAD
  source: hgnc_alias_symbol
  hgnc_symbol: RRAD
  entrez: '6236'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT2
  entrez: '6773'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5B
  entrez: '6777'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT1
  entrez: '6772'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT4
  entrez: '6775'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5A
  entrez: '6776'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
chemicals:
- word: Perifosine
  source: MESH
  identifier: C105905
- word: ARRY-142886
  source: MESH
  identifier: C517975
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Ruxolitinib
  source: MESH
  identifier: C540383
- word: Rapamycin
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4209854__F3
redirect_from: /figures/PMC4209854__F3
figtype: Figure
---
